Trial Profile
Feasibility study of weekly nanoparticle albumin-bound paclitaxel for patients with metastatic breast cancer (HBCC1101).
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2015
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 21 Jan 2014 Planned End Date changed from 30 Mar 2014 to 30 Mar 2015 as reported by University Hospital Medical Information Network - Japan record.
- 09 Jul 2013 Planned End Date (30 Mar 2014) added as reported by University Hospital Medical Information Network - Japan.
- 12 Jan 2012 New trial record